무좀 치료 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the tinea pedis treatment market size was valued at USD 1.44 billion in 2025 and estimated to grow from USD 1.5 billion in 2026 to reach USD 1.84 billion by 2031, at a CAGR of 4.14% during the forecast period (2026-2031).

This report is Segmented by Drug Class (Azoles, Allylamines/Benzylamines, and More), Disease Type (Interdigital Tinea Pedis, Plantar, Vesicular/Inflammatory), Route of Administration (Oral, Topical), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Tinea Pedis Treatment Market Trends and Insights

Growing Prevalence of Superficial Fungal Infections

Global dermatophyte infection rates remain stubbornly high at 20-25%, underlining an enduring public-health challenge. Shifts in species distribution, most notably the geographic spread of Trichophyton indotineae, heighten diagnostic complexity and necessitate broader mycological testing. Urban densification raises humidity in living quarters, creating near-perfect growth conditions for pathogens. Wider immunosuppression from oncologic and transplant therapies further expands the vulnerable population. Documented infection clusters among beach volleyball athletes show how lifestyle exposure adds another transmission layer. Higher baseline disease incidence ensures sustained demand across every therapeutic class in the Tinea pedis treatment market.

Expanding Geriatric & Diabetic Populations

Diabetes mellitus triples the odds of foot mycoses, driven by vascular impairment and reduced immune vigilance. Older adults likewise experience diminished skin integrity and slower epidermal turnover, supporting fungal colonization. Diabetic foot-ulcer episodes can exceed USD 50,000 in direct costs, spurring early prophylactic antifungal use in endocrinology clinics. Long-term care facilities create high-density contact environments that enable rapid organism spread, reinforcing formulary preference for broad-spectrum topicals. Consequently, the Tinea pedis treatment market increasingly integrates patient-education modules on foot hygiene within routine chronic-disease management.

Low Patient Adherence & High Reinfection Rates

Real-world studies reveal barely one-third of clotrimazole-betamethasone prescriptions correspond to confirmed fungal cases, underscoring diagnostic inertia. Therapy cessation typically occurs once itching subsides, even though standard regimens advise 2-4 additional weeks of application. Reinfection thrives in untreated footwear; fungal spores survive for months in warm, moist shoe interiors. Financial constraints steer patients toward lower-potency generics, prolonging pathogen carriage. Primary-care practitioners, who write 40% of antifungal scripts in the United States, often lack specialized dermatomycology training. Persistent treatment gaps dampen volume growth in the Tinea pedis treatment market.

Other drivers and restraints analyzed in the detailed report include:

1. OTC Switch-Friendly Regulatory Stance in US & EU
2. Wider E-Commerce Access to Antifungals
3. Stringent Approval Timelines for Novel Systemic Agents

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Azoles delivered, translating to 49.02% slice of the Tinea pedis treatment market in 2025. Durable physician familiarity and favorable oral bioavailability sustain their role, despite mutational hotspots diminishing sensitivity in select strains. Allylamines and benzylamines, anchored by terbinafine, are the fastest-advancing cohort at a 7.39% CAGR through 2031, buoyed by shorter therapy windows and high mycological cure rates. Polyenes attract niche adoption for refractory cases, with new lipid-based derivatives aiming to balance potency and nephrotoxicity. Combination topical steroids integrated with broad-spectrum antifungals address concomitant inflammation, improving adherence. Looking ahead, echinocandin-like molecules and hydroxy-pyridone derivatives populate early pipelines, signalling additional diversification within the Tinea pedis treatment market.

Second-generation azoles fend off emerging resistance better than first-generation cousins, retaining efficacy against T. indotineae in vitro. Meanwhile, povidone-iodine 10% recently secured Category I FDA status after demonstrating 68.4% cure rates in double-blind trials. Developers are also pairing azoles with penetration enhancers to elevate stratum corneum drug concentrations. Collectively, these developments keep the segment ahead in absolute revenue, yet the differential growth momentum clearly favors allylamines as prescribers seek high-speed pathogen eradication.

Interdigital presentations generated 36.35% of the tinea pedis treatment market turnover in 2025, reflecting everyday exposure to occlusive footwear and communal surfaces. Clinicians usually manage these with low-cost topicals, making the category volume-rich but value-moderate. Vesicular or inflammatory forms, however, manifest blister clusters and intense pruritus, frequently requiring systemic intervention and thereby fetching higher per-patient spend. The vesicular segment is on course for a 9.12% CAGR, the fastest among disease subtypes, as enhanced diagnostic platforms spotlight previously under-recognized cases.

Plantaris or moccasin variants produce hyperkeratotic soles, demanding keratolytic pre-treatment plus long-haul antifungal regimens, particularly in diabetics. Rising misuse of topical steroids in primary care contributes to tinea incognito, a presentation that blurs classical features and delays correct diagnosis. Furthermore, sexually transmitted dermatophytosis cases attributable to T. mentagrophytes genotype VII have surfaced, necessitating wider sexual-health screening integration. These dynamics introduce therapeutic nuance, prompting formulary committees to stock a broader array of systemic options.

Complete Report Scope:

• By Drug Class
  • Azoles
  • Allylamines/-Benzylamines
  • Polyenes
  • Others (Echinocandins, Steroid Combos, Novel Agents)
• By Disease Type
  • Interdigital Tinea Pedis
  • Plantar (Moccasin)
  • Vesicular/Inflammatory
• By Route of Administration
  • Oral
  • Topical
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated the highest regional revenue, capturing 37.29% of the Tinea pedis treatment market size in 2025. Worryingly, the first US cases of terbinafine-resistant T. mentagrophytes genotype VII emerged in New York City in 2024, prompting guideline updates and heightened laboratory scrutiny. The region is also the first to operationalize ACNU digital self-selection portals, potentially widening OTC conversion rates.

Asia-Pacific stands out as the fastest-growing arena, projected at a 9.74% CAGR through 2031. Explosive smartphone adoption, combined with rising disposable incomes, will fuel e-pharmacy expansion. India recorded pharmaceutical sector growth in April 2024, helped by surging terbinafine hydrochloride exports. Yet the region's reliance on a concentrated API manufacturing base introduces supply-disruption risk whenever environmental or regulatory shocks hit production clusters.

Europe commands mature reimbursement systems and benefits from cohesive pharmacovigilance under the EMA. Rezafungin's December 2023 approval signals policymakers' willingness to fast-track mycology innovation. Cold, damp winters extend therapeutic seasonality, particularly in Northern Europe. Elsewhere, Middle East-Africa and South America register modest but rising demand as dermatology services proliferate and health-insurance penetration widens. The global migration of resistant Trichophyton species reinforces the need for cross-regional strain monitoring to inform empiric therapy.

1. GlaxoSmithKline
2. Pfizer
3. Bayer
4. Bausch Health
5. Sun Pharmaceuticals Industries
6. Glenmark Pharmaceuticals
7. Teva Pharmaceutical Industries
8. Amneal Pharmaceuticals
9. Viatris
10. Sebela Pharmaceuticals
11. Advantice Health (Kerasal)
12. Johnson & Johnson (Kenvue OTC)
13. Novartis AG (former Lamisil IP)
14. Perrigo Company
15. Zydus Group
16. Cipla
17. Almirall S.A.
18. Astellas Pharma
19. Lupin
20. Mankind Pharma Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Prevalence of Superficial Fungal Infections
  • 4.2.2 Expanding Geriatric & Diabetic Populations
  • 4.2.3 OTC Switch-Friendly Regulatory Stance in US & EU
  • 4.2.4 Wider E-Commerce Access to Antifungals
  • 4.2.5 Military & Athletic Communal Facility Hygiene Mandates
  • 4.2.6 Rise of Copper-Oxide Textile Integrations in Socks & Footwear
• 4.3 Market Restraints
  • 4.3.1 Low Patient Adherence & High Reinfection Rates
  • 4.3.2 Stringent Approval Timelines for Novel Systemic Agents
  • 4.3.3 Increasing Counterfeit Topical Formulations Online
  • 4.3.4 Emerging Triazole Resistance in Trichophyton Species
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers/Consumers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitute Products
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value in USD)

• 5.1 By Drug Class
  • 5.1.1 Azoles
  • 5.1.2 Allylamines/-Benzylamines
  • 5.1.3 Polyenes
  • 5.1.4 Others (Echinocandins, Steroid Combos, Novel Agents)
• 5.2 By Disease Type
  • 5.2.1 Interdigital Tinea Pedis
  • 5.2.2 Plantar (Moccasin)
  • 5.2.3 Vesicular/Inflammatory
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Topical
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 E-commerce
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 GlaxoSmithKline plc
  • 6.3.2 Pfizer Inc.
  • 6.3.3 Bayer AG
  • 6.3.4 Bausch Health Companies Inc.
  • 6.3.5 Sun Pharmaceutical Industries Ltd
  • 6.3.6 Glenmark Pharmaceuticals Ltd
  • 6.3.7 Teva Pharmaceutical Industries Ltd
  • 6.3.8 Amneal Pharmaceuticals Inc.
  • 6.3.9 Viatris Inc.
  • 6.3.10 Sebela Pharmaceuticals Holdings Inc.
  • 6.3.11 Advantice Health (Kerasal)
  • 6.3.12 Johnson & Johnson (Kenvue OTC)
  • 6.3.13 Novartis AG (former Lamisil IP)
  • 6.3.14 Perrigo Company plc
  • 6.3.15 Cadila Healthcare Ltd
  • 6.3.16 Cipla Ltd
  • 6.3.17 Almirall S.A.
  • 6.3.18 Astellas Pharma Inc.
  • 6.3.19 Lupin Ltd
  • 6.3.20 Mankind Pharma Ltd

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment